Bora Pharmaceuticals Co., Ltd.

Total Valuation

Bora Pharmaceuticals Co., Ltd. carries a market capitalization of 54.77B, placing it among publicly traded companies globally. Its enterprise value stands at 75.82B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Bora Pharmaceuticals Co., Ltd. currently has 126.99M shares outstanding.

Valuation Ratios

Bora Pharmaceuticals Co., Ltd. trades at a trailing price-to-earnings ratio of 20.34. The price-to-sales ratio is 3.19, and the price-to-book ratio stands at 7.05.

Enterprise Valuation

On an enterprise value basis, Bora Pharmaceuticals Co., Ltd. trades at an EV/EBITDA multiple of 23.01 and an EV/FCF ratio of 12.81. The EV/Sales ratio of 3.99 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 23.01 provides insight into valuation relative to core operating earnings.

Financial Position

Bora Pharmaceuticals Co., Ltd. maintains a current ratio of 1.45, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 104.33, indicating elevated leverage, while an interest coverage ratio of 6.80 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Bora Pharmaceuticals Co., Ltd. posts a return on equity of 37.27 and a return on invested capital of 7.89.

Taxes

Over the trailing twelve months, Bora Pharmaceuticals Co., Ltd. has paid 829.85M in income taxes, reflecting an effective tax rate of 15.72.

Stock Price Statistics

Bora Pharmaceuticals Co., Ltd.'s stock has declined approximately -33.98631% over the past 52 weeks. The 50-day moving average sits at 395.82, while the 200-day moving average is 503.98.

Income Statement

Over the trailing twelve months, Bora Pharmaceuticals Co., Ltd. generated 19.01B in revenue and converted that into 2.98B in net income, yielding earnings per share of 34.24. EBITDA reached 3.30B, while operating income came in at 3.30B.

Balance Sheet

Bora Pharmaceuticals Co., Ltd. holds 5.14B in cash and equivalents against 18.23B in total debt, resulting in a net debt position of 12.36B. Total book value stands at 8.60B, with working capital of 6.02B providing operational flexibility.

Cash Flow

Bora Pharmaceuticals Co., Ltd. produced 4.50B in operating cash flow over the past twelve months. After subtracting -1.01B in capital expenditures, free cash flow totaled 3.50B - equivalent to 28.14 per share.

Margins

Bora Pharmaceuticals Co., Ltd. operates with a gross margin of 41.30, reflecting its pricing power and cost economics. The operating margin of 17.33 and net profit margin of 15.68 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Bora Pharmaceuticals Co., Ltd.'s most recent stock split took place on August 4, 2025 with a 1000:1199 split ratio.

Scores

Bora Pharmaceuticals Co., Ltd. posts an Altman Z-Score of 2.57, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.